abstract |
The present invention provides pharmaceutical compositions of altered release properties for treating Crohn's disease and inflammatory bowel disease (IBD), such as ulcerative colitis, wherein the composition of the present invention is 5-aminosalicylic acid (5-ASA) as an active ingredient. And, by means of releasing an appropriate amount of 5-ASA in the small and large intestine, to obtain clinically important ubiquitous effect characteristics and for targeted release. |